# A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

> **NCT03762850** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Travere Therapeutics, Inc.** · enrollment: 406 (actual)

## Conditions studied

- Immunoglobulin A Nephropathy

## Interventions

- **DRUG:** sparsentan
- **DRUG:** irbesartan
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT03762850
- **Lead sponsor:** Travere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-11
- **Primary completion:** 2023-08-07
- **Final completion:** 2026-07
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03762850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03762850, "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03762850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*